Bob Löwenberg

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (19)

Collaborators (9)

Jesús María Hernández-Rivas

Universidad de Salamanca

Ariel Wang

University of Oxford

UNITED KINGDOM

Agnieszka Wierzbowska

Medical University of Lodz

Charles Craddock

University of Birmingham

UNITED KINGDOM

Niels Asger Jakobsen

University of Oxford

UNITED KINGDOM

Richard Larson

University of Chicago

UNITED STATES

Thomas Pabst

Lars Bullinger

Charité University Medicine

Hendrik Veelken

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Bob Löwenberg

Research Interests

Explore related searches

Contact this professor

Articles (19)

Collaborators (9)

Jesús María Hernández-Rivas

Ariel Wang

Agnieszka Wierzbowska

Charles Craddock

Niels Asger Jakobsen

Richard Larson

Thomas Pabst

Lars Bullinger

Hendrik Veelken

Make your next move.

Bob Löwenberg

Research Interests

Explore related searches

Contact this professor

Articles (19)

Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia

A revised prognostic model for patients with acute myeloid leukemia and first relapse

Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients

Double mutant DNMT3A AML: a unique subtype experiencing increased DNA damage and poor prognosis

Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML

Disease characteristics and outcomes of acute myeloid leukemia in germline RUNX1 deficiency (Familial Platelet Disorder with associated Myeloid Malignancy)

Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission

The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Risk Stratification in Older Intensively Treated Patients With AML

Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.

DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia

Towards precision medicine for AML

Prof. Anton Hagenbeek 1948–2021: Father of MRD and Lymphoma Expert

Professor Anton Hagenbeek 1948–2021: Father of MRD and lymphoma expert

RUNX1 germline variants in RUNX1-mutant AML: how frequent?

The long road: improving outcome in elderly “unfit” AML?

Collaborators (9)

Jesús María Hernández-Rivas

Ariel Wang

Agnieszka Wierzbowska

Charles Craddock

Niels Asger Jakobsen

Richard Larson

Thomas Pabst

Lars Bullinger

Hendrik Veelken

Make your next move.